Novo Nordisk shares jump 7% on promising weight loss trial results; Eli Lilly dips
Jonathan Raa | Nurphoto | Getty Images Novo Nordisk shares climbed 7% on Thursday, hitting a fresh record high after the Danish pharmaceutical giant reported positive early trial data for a new experimental weight loss drug. The company told an investor meeting that the Phase I trial of its highly-anticipated obesity drug amycretin showed a … Read more